1. 160P COLUMBIA-1: A phase Ib/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC). (December 2022) Authors: Segal, N.H.; Tie, J.; Kopetz, S.; Ducreux, M.P.; Chen, E.; Dienstmann, R.; Hollebecque, A.; Reilley, M.; Elez Fernandez, M.E.; Cosaert, J.; Cain, J.; Hernandez, M.; Hewson, N.; Cooper, Z.A.; Dressman, M.; Tabernero, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 188P IPH5201 as monotherapy or in combination with durvalumab (D) in advanced solid tumours. (December 2022) Authors: Imbimbo, M.; Hollebecque, A.; Italiano, A.; McKean, M.; Macarulla, T.; Castanon Alvarez, E.; Carneiro, B.A.; Mager, R.; Barnhart, V.; Murtomaki, E.; He, Y.; Cooper, Z.A.; Tu, E.; Linke, A.; Fan, C.; Zhou, D.; Boyer Chammard, A.; Paturel, C.L.; Fraenkel, P.G.; Powderly, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2090 Prognostic score (REGOSCORE) for survival after Regorafenib (RE) treatment for patients (pts) with pretreated metastatic colorectal cancer (mCRC). (September 2015) Authors: Kramar, A.; Paule, B.; Burtin, P; Tougeron, D.; Desseigne, F.; Dourthe, L.M.; Wallet, J.; Etienne, PL.; Mineur, L.; Becuwe, C.; Maes, P; Dauba, J.; Michel, P; Hollebecque, A.; Linot, B.; Morere, J.F.; Fouchardiere, C. De la; Phelip, J.M.; Andre, T.; Adenis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S358 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study. (September 2015) Authors: Fontaniere, C. De La Fouchardiere; Paule, B.; Burtin, P; Wallet, J.; Tougeron, D.; Dourthe, L.M.; Etienne, P.L.; Mineur, L.; Becuwe, C.; Maes, P.; Dauba, J.; Michel, P.; Wendling, J.L.; Linot, B.; Hollebecque, A.; Clisant, S.; Morere, J.F.; Andre, T.; Phelip, J.M.; Adenis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 301 First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors. (September 2015) Authors: Azaro, A.; Rodon, J.; Herranz, M.; Nuciforo, P.; Prudkin, L.; Lopez-Busto, N.; Balandraud, S.; Cattan, V.; Jacquet-Bescond, A.; Marfai, L.; Pauly, J.; Postel-Vinay, S.; Hollebecque, A.; Soria, J.C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 319 Risk factors of screen-failures in phase 1 clinical trials. (September 2015) Authors: Kempf, E.; Lemoine, N.; Tergemina-Clain, G.; Turpin, A.; Postel-Vinay, S.; Lanoy, E.; Soria, J.C.; Hollebecque, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 324 Dose-seeking phase I trials (DSPT) of approved molecularly targeted therapies (MTT): Exhaustiveness and readability of published clinical reports. (September 2015) Authors: Cousin, S.; Hollebecque, A.; Isambert, N.; Italiano, A.; Kotecki, N.; Postel-Vinay, S.; Gobbo, J.; Toulmonde, M.; Penel, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 349 Impact of the re-definition of dose-limiting toxicities (DLTs) according to recent recommendations on the DLT rate in phase 1 trials of molecularly targeted agents. (September 2015) Authors: Helissey, C.; Poterie, A.; Massard, C.; Hollebecque, A.; Paoletti, X.; Lanoy, E.; Soria, J.C.; Postel-Vinay, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028. (September 2015) Authors: Bang, Y.J.; Doi, T.; Braud, F. De; Piha-Paul, S.; Hollebecque, A.; Razak, A.R. Abdul; Lin, C.C.; Ott, P.A.; He, A.R.; Yuan, S.S.; Koshiji, M.; Lam, B.; Aggarwal, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors. (December 2016) Authors: Varga, A.; Soria, J.C.; Hollebecque, A.; LoRusso, P.; Vaishampayan, U.; Okrah, K.; Huang, S.M.A.; Murray, E.; Sanabria-Bohorquez, S.; Tagen, M.; Dokainish, H.; Mueller, L.; Burris, H. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗